Open AccessAn allosteric site on MKP5 reveals a strategy for small-molecule inhibition
Author(s) -
Zachary T. K. Gannam,
Kisuk Min,
Shanelle R. Shillingford,
Lei Zhang,
James Herrington,
Laura Abriola,
Peter C. Gareiss,
Georgios Pantouris,
Argyrios Tzouvelekis,
Naftali Kaminski,
Xinbo Zhang,
Jun Yu,
Haya Jamali,
Jonathan A. Ellman,
Elias Lolis,
Karen S. Anderson,
Anton M. Bennett
Publication year - 2020
Publication title -
science signaling
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.659
H-Index - 154
eISSN - 1937-9145
pISSN - 1945-0877
DOI - 10.1126/scisignal.aba3043
Subject(s) - allosteric regulation , small molecule , phosphatase , chemistry , allosteric enzyme , microbiology and biotechnology , biology , biochemistry , enzyme
The mitogen-activated protein kinase (MAPK) phosphatases (MKPs) have been considered "undruggable," but their position as regulators of the MAPKs makes them promising therapeutic targets. MKP5 has been suggested as a potential target for the treatment of dystrophic muscle disease. Here, we identified an inhibitor of MKP5 using a p38α MAPK-derived, phosphopeptide-based small-molecule screen. We solved the structure of MKP5 in complex with this inhibitor, which revealed a previously undescribed allosteric binding pocket. Binding of the inhibitor to this pocket collapsed the MKP5 active site and was predicted to limit MAPK binding. Treatment with the inhibitor recapitulated the phenotype of MKP5 deficiency, resulting in activation of p38 MAPK and JNK. We demonstrated that MKP5 was required for TGF-β1 signaling in muscle and that the inhibitor blocked TGF-β1-mediated Smad2 phosphorylation. TGF-β1 pathway antagonism has been proposed for the treatment of dystrophic muscle disease. Thus, allosteric inhibition of MKP5 represents a therapeutic strategy against dystrophic muscle disease.